Joshua Cohen Sells 7,715 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Joshua Cohen sold 7,715 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $11.09, for a total transaction of $85,559.35. Following the completion of the sale, the chief executive officer owned 3,317,586 shares of the company’s stock, valued at approximately $36,792,028.74. The trade was a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX stock opened at $12.21 on Friday. Amylyx Pharmaceuticals, Inc. has a 52-week low of $2.60 and a 52-week high of $16.96. The company has a 50-day simple moving average of $13.02 and a two-hundred day simple moving average of $11.31. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.78 and a beta of -0.31.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. On average, sell-side analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AMLX has been the topic of several research reports. Citigroup lifted their price objective on shares of Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Robert W. Baird lifted their price target on shares of Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Bank of America increased their price objective on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, October 3rd. The Goldman Sachs Group raised their target price on Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, September 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.25.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd purchased a new position in shares of Amylyx Pharmaceuticals in the third quarter valued at $48,000. California State Teachers Retirement System purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at about $28,000. BNP Paribas Financial Markets increased its position in shares of Amylyx Pharmaceuticals by 433.2% during the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after buying an additional 5,904 shares during the period. Ameritas Investment Partners Inc. purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth about $45,000. Finally, Legal & General Group Plc bought a new position in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $47,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.